Riggs Asset Management’s Fortress Biotech FBIO Stock Holding History

Riggs Asset Management’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-60	Closed	-$3K	–	315
2021 Q1	$3K	Hold	60	–	–	﹤0.01%	254
2020 Q4	$3K	Buy	+60	New	+$2.6K	﹤0.01%	237
2020 Q3	–	Sell	-60	Closed	-$2K	–	186
2020 Q2	$2K	Buy	+60	New	+$2.23K	﹤0.01%	223
2020 Q1	–	Sell	-60	Closed	-$2K	–	262
2019 Q4	$2K	Buy	+60	New	+$1.54K	﹤0.01%	260

Other funds holding FBIO

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Riggs Asset Management's FBIO Position: Q2 2021 in Review

Riggs Asset Management sold out of Fortress Biotech (FBIO) in Q2 2021, closing a stake of 60 shares — an estimated $3K sold.

Riggs Asset Management first reported a position in FBIO in Q4 2019 and held it in 4 quarters. The position peaked at $3K in Q1 2021. 84 funds tracked by Wall St. Rank hold FBIO as of Q2 2021.

Riggs Asset Management reported no remaining Fortress Biotech position as of Q2 2021 after selling out during the quarter.
Riggs Asset Management sold 60 Fortress Biotech shares in Q2 2021, an estimated $3K.
Riggs Asset Management first reported a position in Fortress Biotech in Q4 2019 and held it in 4 quarters.
Riggs Asset Management's Fortress Biotech position peaked at $3K in Q1 2021.
84 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2021.

Based on Riggs Asset Management's 13F filing for Q2 2021, filed 16 Jul 2021.